AI-Designed AH-001 Completes US Phase I Trial With Strong Result
29 Oct 2025 //
PR NEWSWIRE
AnHorn Medicines: First Subject Dosed in AH-001 Phase I US Trial
26 Mar 2025 //
PR NEWSWIRE
AnHorn Medicines Presents Research of Novel Protein Degrader for Topical Use
15 May 2023 //
PR NEWSWIRE

Market Place
Sourcing Support